Private Advisor Group’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Private Advisor Group’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17,075	Closed	-$7K	–	1176
2015 Q4	$7K	Hold	17,075	–	–	﹤0.01%	1096
2015 Q3	$10K	Hold	17,075	–	–	﹤0.01%	1029
2015 Q2	$9K	Hold	17,075	–	–	﹤0.01%	1062
2015 Q1	$14K	Buy	17,075 +3,000	+21%	+$2.47K	﹤0.01%	992
2014 Q4	$11K	Sell	14,075 -7,500	-35%	-$6.86K	﹤0.01%	983
2014 Q3	$22K	Hold	21,575	–	–	﹤0.01%	1134
2014 Q2	$19K	Buy	+21,575	New	+$25.9K	﹤0.01%	891

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Home Federal Bank of Tennessee Knoxville, Tennessee $465M AUM 18.18% 1-Year Est. Return

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Private Advisor Group's PVCT Position: Q1 2016 in Review

Private Advisor Group sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2016, closing a stake of 17,075 shares — an estimated $7K sold.

Private Advisor Group first reported a position in PVCT in Q2 2014 and held it in 7 quarters. The position peaked at $22K in Q3 2014. 44 funds tracked by Wall St. Rank hold PVCT as of Q1 2016.

Private Advisor Group reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2016 after selling out during the quarter.
Private Advisor Group sold 17,075 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2016, an estimated $7K.
Private Advisor Group first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 7 quarters.
Private Advisor Group's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $22K in Q3 2014.
44 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2016.

Based on Private Advisor Group's 13F filing for Q1 2016, filed 13 May 2016.